Pulse.

a daily field guide to health research that matters

◆ Console

‹ Mon · 2 Nov 2026
Novel or significantly improved treatment

Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Measuring spleen size on imaging may help identify CAR-T therapy candidates most likely to survive, improving how doctors select patients for this intensive treatment.

This cohort study identified baseline spleen volume as an independent prognostic biomarker for survival after CD19 CAR-T cell therapy in r/r DLBCL. The finding introduces a clinically accessible imaging measure that could improve CAR-T patient selection and risk stratification in a field with highly variable outcomes.

What the study was

Study design
Retrospective cohort study
Population
r/r DLBCL patients receiving CD19-directed CAR-T cell therapy
Category
Treatment Innovation
Maturity
Validated
Journal
Hematological oncology

Why it surfaced

Novel imaging biomarker for CAR-T patient selection in DLBCL; immediately applicable to this rapidly expanding and resource-intensive therapy.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.